![[APHA]](/images/logo_apha.svg){kind=logo}
The safety and quality of cancer care in Australia is expected to rise to new levels of excellence following Icon Group's new collaboration with medical technology company RTsafe.
Icon, the country's largest dedicated cancer care provider, has bought two RTsafe PRIME phantoms to use across its network of more than 40 centres nationwide.
The first of their kind to be installed in Australia, the PRIME phantoms will help to assess the entire treatment chain from imaging and planning through patient setup and dose delivery.
"At Icon we have a strong track record and commitment to investing in the latest cutting-edge treatments and technologies to improve the way we deliver care," said Trent Aland, Icon's Executive Manager of Clinical Care.
"The introduction of these phantoms will further enhance our quality assurance and enable the safe delivery of complex and highly-advanced treatments for the benefit of teams and our patients."
The PRIME, an anthropomorphic, 3D-printed head phantom, combines true-to-life human anatomy with advanced point, 2D and 3D dosimetry to deliver true end-to-end quality assurance.
The first-to-market PRIME phantom equipment by RTsafe
Combined with RTsafe's independent remote dosimetry services, it enables a comprehensive verification of complex stereotactic and other high-precision radiotherapy treatments.
It is the exclusive phantom used by the International Stereotactic Radiosurgery Society (ISRS) in its certification service, providing centres with a recognised, standardised pathway to demonstrate the accuracy and robustness of their radiosurgery programs.
"Our collaboration with Icon reflects a shared ambition to continually elevate the standards of cancer care," said RTsafe's Founder and Chief Scientific Officer, Evangelos Pappas.
"Our goal is to bring certainty to radiotherapy – giving clinicians robust, independent evidence that complex treatments are delivered as intended, and giving patients peace of mind that their safety is carefully safeguarded at every step."
Icon hopes the collaboration with RTsafe will also open new avenues for clinical and research initiatives across its network in Australia and its operations in Asia-Pacific and the United Kingdom.
Read more: 'Major milestone' for advanced cancer care in Australia
Read more: Trial aims to improve precision of cancer care
Next Safety And Quality:
3/2/2026 'Unprecedented' safety award for Bethesda Health Care
Previous Safety And Quality:
18/12/2025 Valve innovation 'lowers chance of heart failure'